To advance flow diversion therapy, Shield Technology™ addresses one of its common barriers: material thrombogenicity.

Through covalently bonding phosphorylcholine to the surface of the implant, Shield Technology™ enhances the Pipeline™ Flex embolization device to achieve a scientifically proven reduction in implant material thrombogenicity as shown through in-vitro studies.1,2*

Human Blood Loop Model Results¹*

94% reduction in platelet activation¹*

Mean Peak Thrombin (nM)²*

FLEX WITH SHIELD (23.68)  
FLEX (52.37)

55% reduction in peak thrombin²*

* Data is derived from the referenced bench studies and may not be representative of clinical performance.
In-vivo testing shows that Shield Technology™ led to earlier and more even neointima formation\(^3\) with less hyperplasia and comparable aneurysm occlusion rates as the Pipeline™ Flex embolization device.\(^4\)

Analysis with Optical Coherence Tomography shows that the Pipeline™ Flex device with Shield Technology™ demonstrates a homogenous and concentric tissue response.\(^3\)

* Data is derived from the referenced animal studies and may not be representative of clinical performance.
**IMPROVES PERFORMANCE**

Shield Technology™ improves the customer experience through improvements in delivery and resheathing force through tortuosity.\(^5\)

<table>
<thead>
<tr>
<th></th>
<th>Delivery Force (N)</th>
<th>Resheathing Force (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLEX (PED-400-35)</td>
<td>6.5</td>
<td>2.4</td>
</tr>
<tr>
<td>FLEX WITH SHIELD (PED2-400-35)</td>
<td>5.2</td>
<td>2.1</td>
</tr>
</tbody>
</table>

The modified surface of the implant exhibits hydrophilic properties, decreasing delivery and resheathing forces by **20%** and **12%** respectively.\(^5\)

The Phenom™ 27 Catheter, specifically designed for flow diversion, incorporates a hybrid coil-braid design to maintain stability and improve procedural performance.\(^8\)

* Data is derived from the referenced bench studies and may not be representative of clinical performance.
A clinically proven, cobalt-chromium and platinum-tungsten flow diversion device that's resheathable and redeployable.

**PUFS Study Results**^6^*

- **95%** Occlusion at 5 year follow-up
- **0%** Recurrence at 5 years after initial occlusion

* The PUFS study only included the Pipeline™ embolization device. The Pipeline™ Flex embolization device contains the same implant as the Pipeline™ embolization device.

**NOW SHIELDED BY SCIENCE.**

**PFLEX and SHIELD Combined Results:** Wide-Necked ICA Population^7^

- **3.1%** Primary Safety Endpoint
- **75.7%** Primary Efficacy Endpoint with 79.2% Complete Occlusion
- **98.1%** Device Deployment Success with Average 1.1 Deployed per Subject

* Primary Safety Endpoint defined as major stroke in the territory supplied by the treated artery or neurologic death through 1-year post-procedure.

** Primary Efficacy Endpoint defined as complete aneurysm occlusion without significant parent artery stenosis (≤50%) or retreatment of the target aneurysm through 1-year post procedure.
PIPET™ FLEX EMBOLIZATION DEVICE WITH SHIELD TECHNOLOGY® ESSENTIAL PRESCRIBING INFORMATION (EPI) STATEMENT: CAUTION: Federal (USA) law restricts this device to sale, distribution and use by or on the order of a physician. Indications, contraindications, warnings and precautions: is for the treatment of intracranial aneurysms (IAs) with provisional bare stent deployment to exclude flow of blood into the aneurysm sac. It is intended for patients who have not received dual antiplatelet agents prior to the procedure. 5) Patients in whom the parent vessel size does not fall within the range of 3.0 to 7.0 mm. 6) Patients in whom a pre-existing stent is in place in the parent artery at the target aneurysm location. 7) Patients in whom the parent vessel size does not fall within the range of 3.0 to 7.0 mm.

Precautions:

1. The Phenom™ Catheters are intended for the introduction of interventional devices or diagnostic agents into the neuro, peripheral, and coronary vasculatures.
2. The Phenom™ Catheters are intended for single use only. Store in a cool, dry place. Carefully inspect the sterile package and device components prior to use to verify that they have not been damaged during shipping. Do not use kinked or damaged components.
3. The Phenom™ Catheters are intended for single use only. Store in a cool, dry place. Carefully inspect the sterile package and device components prior to use to verify that they have not been damaged during shipping. Do not use kinked or damaged components.

Medtronic
9775 Toledo Blvd
Irving, CA 92618
USA
Tel 877.526.7890
Fax 763.526.7888
medtronic.com

UC21L14926 Rev B 2021 Medtronic. All rights reserved. Medtronic logo and Further Together are trademarks of Medtronic. All other brands are trademarks of their respective owners.

PHENOM™ CATHETER INDICATIONS FOR USE: This PHENOM™ Catheters are intended for the introduction of interventional devices or diagnostic agents into the neuro peripheral, and coronary vasculatures. CAUTION: Federal (USA) law restricts this device to sale, distribution and use by or on the order of a physician. Indications, contraindications, warnings and precautions: is for the treatment of intracranial aneurysms (IAs) with provisional bare stent deployment to exclude flow of blood into the aneurysm sac. It is intended for patients who have not received dual antiplatelet agents prior to the procedure. 5) Patients in whom the parent vessel size does not fall within the range of 3.0 to 7.0 mm.

Precautions:

1. The Phenom™ Catheters are intended for single use only. Store in a cool, dry place. Carefully inspect the sterile package and device components prior to use to verify that they have not been damaged during shipping. Do not use kinked or damaged components.